HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

S30972-1

structure in first source

Also Known As:

S 30972-1

Networked: 1 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Atassi, Ghanem: 1 article (08/2002)
2.	Genissel, Patrick: 1 article (08/2002)
3.	Goldstein, Solo: 1 article (08/2002)
4.	Guilbaud, Nicolas: 1 article (08/2002)
5.	Guillonneau, Claude: 1 article (08/2002)
6.	Kraus-Berthier, Laurence: 1 article (08/2002)
7.	Léonce, Stéphane: 1 article (08/2002)
8.	Parker, Tracy: 1 article (08/2002)
9.	Pierré, Alain: 1 article (08/2002)

Related Diseases

1.	Lewis Lung Carcinoma 08/01/2002 - "In vivo, S 30972-1 induced more long-term survivors than S 16020-2 among mice with Lewis lung carcinoma and sensitive or multidrug resistant P388 leukemias. "
2.	Neoplasms (Cancer) 08/01/2002 - "Although tumor cell proliferation and accumulation of cells in the G2 phase of the cell cycle were similarly affected by the two compounds after a continuous exposure (IC50 values of 30-50 n M), S 30972-1 was about tenfold less potent than S 16020-2 after short exposures. " 08/01/2002 - "To compare the pharmacological profile of S 30972-1 and S 16020-2 in vitro and in vivo and to investigate whether S 30972-1 could act as a prodrug of S 16020-2. The two compounds were compared in vitro in terms of their activity in inhibiting cellular proliferation and perturbing the cell cycle and in vivo in terms of their antitumor activity in murine transplantable tumors and human orthotopic models. "
3.	Leukemia 08/01/2002 - "In vivo, S 30972-1 induced more long-term survivors than S 16020-2 among mice with Lewis lung carcinoma and sensitive or multidrug resistant P388 leukemias. "
4.	Carcinoma (Carcinomatosis) 08/01/2002 - "The growth of Colon 38 carcinoma was slightly more inhibited by S 30972-1 than S 16020-2. In the more relevant human orthotopic models, using the optimal doses of each drug, 160 mg/kg S 30972-1 was significantly more active than 80 mg/kg S 16020-2 in the NCI-H460 lung carcinoma. "

Related Drugs and Biologics

1.	Prodrugs
2.	S 16020-2